Mediterranean diet and multi-ingredient-based interventions for the management of non-alcoholic fatty liver disease

Nutrients

Volumn 9, Issue 10, 2017, Pages

  Suárez, Manuel ^a   Boqué, Noemí ^b   del Bas, Josep M ^b   Mayneris Perxachs, Jordi ^b   Arola, Lluís ^a,b   Caimari, Antoni ^b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b CENTRE TECNOLÒGIC DE CATALUNYA   (Spain)

Author keywords

Hepatic steatosis; Mediterranean diet; Multi ingredient; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Omics technologies; Polyunsaturated fatty acids; Silymarin; Synbiotics; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CYSTEINE; DOCOSAHEXAENOIC ACID; FUCOXANTHIN; GLUTATHIONE; LINOLEIC ACID; PHOSPHATIDYLCHOLINE; POLYUNSATURATED FATTY ACID; SILIBININ; SYNBIOTIC AGENT; VEGETABLE OIL; VITAMIN D;

CLINICAL EFFECTIVENESS; DIET SUPPLEMENTATION; DIETARY COMPLIANCE; DISEASE ASSOCIATION; EXERCISE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIVER FUNCTION; MEDITERRANEAN DIET; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRIGENOMICS; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; ADOLESCENT; ADULT; CHILD; DIET THERAPY; DIETARY SUPPLEMENT; FEMALE; HEALTHY DIET; MALE; MIDDLE AGED; NUTRITIONAL STATUS; NUTRITIONAL VALUE; PROCEDURES; PROTECTION; RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; DIET, MEDITERRANEAN; DIETARY SUPPLEMENTS; FEMALE; HEALTHY DIET; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRIGENOMICS; NUTRITIONAL STATUS; NUTRITIVE VALUE; PROTECTIVE FACTORS; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85030104292     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9101052     Document Type: Review

References (141)

1. Abenavoli, L.; Milic, N.; Di Renzo, L.; Preveden, T.; Medic-Stojanoska, M.; De Lorenzo, A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J. Gastroenterol. 2016, 22, 7006–7016. [CrossRef] [PubMed]
2. Benedict, M.; Zhang, X. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol. 2017, 9, 715–732. [CrossRef] [PubMed]
3. Younossi, Z.M.; Blissett, D.; Blissett, R.; Henry, L.; Stepanova, M.; Younossi, Y.; Racila, A.; Hunt, S.; Beckerman, R. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016, 64, 1577–1586. [CrossRef] [PubMed]
4. Farrell, G.C.; Wong, V.W.-S.; Chitturi, S. NAFLD in Asia—As common and important as in the West. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 307–318. [CrossRef] [PubMed]
5. Neuschwander-tetri, B.A. Hepatic Lipotoxicity and the Pathogenesis of Nonalcoholic Steatohepatitis: The Central Role of Nontriglyceride Fatty Acid Metabolites. Hepatology 2010, 52, 774–788. [CrossRef] [PubMed]
6. Day, C.P.; James, O.F.W.; Macdonald, G.; Cowley, L.; Walker, N.; Ward, P.; Jazwinska, E.; Powell, L.; Fromenty, B.; Pessayre, D. Steatohepatitis: A tale of two “hits”? Gastroenterology 1998, 114, 842–845. [CrossRef]
7. Alkhouri, N. Lipotoxicity in nonalcoholic fatty liver disease: Not all lipids are created equal. Expert Rev. Gastroenterol. Hepatol. 2009, 3, 445–451. [CrossRef] [PubMed]
8. Cusi, K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. Gastroenterology 2012, 142, 711–725.e6. [CrossRef] [PubMed]
9. Buzzetti, E.; Pinzani, M.; Tsochatzis, E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016, 65, 1038–1048. [CrossRef] [PubMed]
10. Kozlitina, J.; Smagris, E.; Stender, S.; Nordestgaard, B.G.; Zhou, H.H.; Tybjærg-Hansen, A.; Vogt, T.F.; Hobbs, H.H.; Cohen, J.C. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2014, 46, 352–356. [CrossRef] [PubMed]
11. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142, 1592–1609. [CrossRef] [PubMed]
12. Bedossa, P.; Patel, K. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. Gastroenterology 2016, 150, 1811–1822.e4. [CrossRef] [PubMed]
13. Burt, A.; Lackner, C.; Tiniakos, D. Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification. Semin. Liver Dis. 2015, 35, 207–220. [CrossRef] [PubMed]
14. Fitzpatrick, E.; Dhawan, A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J. Gastroenterol. 2014, 20, 10851–10863. [CrossRef] [PubMed]
15. Papandreou, D.; Andreou, E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J. Hepatol. 2015, 7, 575. [CrossRef] [PubMed]
16. Vizuete, J.; Camero, A.; Malakouti, M.; Garapati, K.; Gutierrez, J. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J. Clin. Transl. Hepatol. 2017, 5, 67–75. [CrossRef] [PubMed]
17. Wettstein, G.; Luccarini, J.-M.; Poekes, L.; Faye, P.; Kupkowski, F.; Adarbes, V.; Defrêne, E.; Estivalet, C.; Gawronski, X.; Jantzen, I., et al. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. Hepatol. Commun. 2017, 1, 524–537. [CrossRef]
18. Haczeyni, F.; Wang, H.; Barn, V.; Mridha, A.R.; Yeh, M.M.; Haigh, W.G.; Ioannou, G.N.; Choi, Y.-J.; McWherter, C.A.; Teoh, N.C.-H., et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol. Commun. 2017, 1, 663–674. [CrossRef]
19. Klebanoff, M.J.; Corey, K.E.; Chhatwal, J.; Kaplan, L.M.; Chung, R.T.; Hur, C. Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology 2017, 65, 1156–1164. [CrossRef] [PubMed]
20. Keating, S.E.; Hackett, D.A.; George, J.; Johnson, N.A. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Hepatol. 2012, 57, 157–166. [CrossRef] [PubMed]
21. Yki-Järvinen, H. Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance. Nutrients 2015, 7, 9127–9138. [CrossRef] [PubMed]
22. Vilar-Gomez, E.; Martinez-Perez, Y.; Calzadilla-Bertot, L.; Torres-Gonzalez, A.; Gra-Oramas, B.; Gonzalez-Fabian, L.; Friedman, S.L.; Diago, M.; Romero-Gomez, M. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015, 149, 367–378.e5. [CrossRef] [PubMed]
23. Andersen, T.; Gluud, C.; Franzmann, M.B.; Christoffersen, P. Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol. 1991, 12, 224–229. [CrossRef]
24. Marchesini, G.; Montesi, L.; El Ghoch, M.; Brodosi, L.; Calugi, S.; Dalle Grave, R. Long-term weight loss maintenance for obesity: A multidisciplinary approach. Diabetes Metab. Syndr. Obes. Targets Ther. 2016, 9, 37. [CrossRef] [PubMed]
25. Bjermo, H.; Iggman, D.; Kullberg, J.; Dahlman, I.; Johansson, L.; Persson, L.; Berglund, J.; Pulkki, K.; Basu, S.; Uusitupa, M., et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: A randomized controlled trial. Am. J. Clin. Nutr. 2012, 95, 1003–1012. [CrossRef] [PubMed]
26. Vessby, B.; Uusitupa, M.; Hermansen, K.; Riccardi, G.; Rivellese, A.A.; Tapsell, L.C.; Nälsén, C.; Berglund, L.; Louheranta, A.; Rasmussen, B.M., et al. KANWU Study Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia 2001, 44, 312–319. [CrossRef] [PubMed]
27. Kastorini, C.-M.; Milionis, H.J.; Esposito, K.; Giugliano, D.; Goudevenos, J.A.; Panagiotakos, D.B. The Effect of Mediterranean Diet on Metabolic Syndrome and its Components: A Meta-Analysis of 50 Studies and 534,906 Individuals. J. Am. Coll. Cardiol. 2011, 57, 1299–1313. [CrossRef] [PubMed]
28. Esposito, K.; Kastorini, C.-M.; Panagiotakos, D.B.; Giugliano, D. Mediterranean diet and metabolic syndrome: An updated systematic review. Rev. Endocr. Metab. Disord. 2013, 14, 255–263. [CrossRef] [PubMed]
29. Lavine, J.E.; Schwimmer, J.B.; Van Natta, M.L.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Abrams, S.H.; Scheimann, A.O.; Sanyal, A.J.; Chalasani, N., et al. Nonalcoholic Steatohepatitis Clinical Research Network Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. JAMA 2011, 305, 1659. [CrossRef] [PubMed]
30. Sanyal, A.J.; Chalasani, N.; Kowdley, K.V.; McCullough, A.; Diehl, A.M.; Bass, N.M.; Neuschwander-Tetri, B.A.; Lavine, J.E.; Tonascia, J.; Unalp, A., et al. NASH CRN Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N. Engl. J. Med. 2010, 362, 1675–1685. [CrossRef] [PubMed]
31. He, X.-X.; Wu, X.-L.; Chen, R.-P.; Chen, C.; Liu, X.-G.; Wu, B.-J.; Huang, Z.-M. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE 2016, 11, e0162368. [CrossRef] [PubMed]
32. Tong, T.Y.N.; Wareham, N.J.; Khaw, K.-T.; Imamura, F.; Forouhi, N.G. Prospective association of the Mediterranean diet with cardiovascular disease incidence and mortality and its population impact in a non-Mediterranean population: The EPIC-Norfolk study. BMC Med. 2016, 14, 135. [CrossRef] [PubMed]
33. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.-I.; Corella, D.; Arós, F.; Gómez-Gracia, E.; Ruiz-Gutiérrez, V.; Fiol, M.; Lapetra, J., et al. PREDIMED Study Investigators Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N. Engl. J. Med. 2013, 368, 1279–1290. [CrossRef] [PubMed]
34. Esposito, K.; Maiorino, M.I.; Bellastella, G.; Chiodini, P.; Panagiotakos, D.; Giugliano, D. A journey into a Mediterranean diet and type 2 diabetes: A systematic review with meta-analyses. BMJ Open 2015, 5, e008222. [CrossRef] [PubMed]
35. Romaguera, D.; Norat, T.; Mouw, T.; May, A.M.; Bamia, C.; Slimani, N.; Travier, N.; Besson, H.; Luan, J.; Wareham, N., et al. Adherence to the Mediterranean Diet Is Associated with Lower Abdominal Adiposity in European Men and Women. J. Nutr. 2009, 139, 1728–1737. [CrossRef] [PubMed]
36. Beunza, J.-J.; Toledo, E.; Hu, F.B.; Bes-Rastrollo, M.; Serrano-Martinez, M.; Sanchez-Villegas, A.; Martinez, J.A.; Martinez-Gonzalez, M.A. Adherence to the Mediterranean diet, long-term weight change, and incident overweight or obesity: The Seguimiento Universidad de Navarra (SUN) cohort. Am. J. Clin. Nutr. 2010, 92, 1484–1493. [CrossRef] [PubMed]
37. Benetou, V.; Trichopoulou, A.; Orfanos, P.; Naska, A.; Lagiou, P.; Boffetta, P.; Trichopoulos, D. Greek EPIC cohort Conformity to traditional Mediterranean diet and cancer incidence: The Greek EPIC cohort. Br. J. Cancer 2008, 99, 191–195. [CrossRef] [PubMed]
38. Sofi, F.; Cesari, F.; Abbate, R.; Gensini, G.F.; Casini, A. Adherence to Mediterranean diet and health status: Meta-analysis. BMJ 2008, 337, 673–675. [CrossRef] [PubMed]
39. Trichopoulou, A.; Costacou, T.; Bamia, C.; Trichopoulos, D. Adherence to a Mediterranean Diet and Survival in a Greek Population. N. Engl. J. Med. 2003, 348, 2599–2608. [CrossRef] [PubMed]
40. Trovato, F.M.; Martines, G.F.; Brischetto, D.; Trovato, G.; Catalano, D. Neglected features of lifestyle: Their relevance in non-alcoholic fatty liver disease. World J. Hepatol. 2016, 8, 1459–1465. [CrossRef] [PubMed]
41. Kontogianni, M.D.; Tileli, N.; Margariti, A.; Georgoulis, M.; Deutsch, M.; Tiniakos, D.; Fragopoulou, E.; Zafiropoulou, R.; Manios, Y.; Papatheodoridis, G. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin. Nutr. 2014, 33, 678–683. [CrossRef] [PubMed]
42. Aller, R.; Izaola, O.; De La Fuente, B.; De Luis, D. Mediterranean diet is associated with liver histology in patients with non alcoholic fatty liver disease. Nutr. Hosp. 2015, 32, 2518–2524. [CrossRef] [PubMed]
43. Ryan, M.C.; Itsiopoulos, C.; Thodis, T.; Ward, G.; Trost, N.; Hofferberth, S.; O’Dea, K.; Desmond, P.V.; Johnson, N.A.; Wilson, A.M. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J. Hepatol. 2013, 59, 138–143. [CrossRef] [PubMed]
44. Katsagoni, C.N.; Egkomiti, A.; Papageorgiou, M.; Ioannidou, P.; Fragopoulou, E.; Papatheodoridis, G.; Kontogianni, M. Improvement in liver function after an intervention based on the Mediterranean diet in patients with non alcoholic fatty liver disease (NAFLD). Clin. Nutr. ESPEN 2016, 13, e57. [CrossRef] [PubMed]
45. Gelli, C.; Tarocchi, M.; Abenavoli, L.; Di Renzo, L.; Galli, A.; De Lorenzo, A. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. World J. Gastroenterol. 2017, 23, 3150–3162. [CrossRef] [PubMed]
46. Trovato, F.M.; Catalano, D.; Martines, G.F.; Patrizia, P.; Trovato, G.M. Mediterranean diet and non-alcoholic fatty liver disease. The need of extended and comprehensive interventions. Clin. Nutr. 2015, 34, 86–88. [CrossRef] [PubMed]
47. Misciagna, G.; Del Pilar Diaz, M.; Caramia, D.V.; Bonfiglio, C.; Franco, I.; Noviello, M.R.; Chiloiro, M.; Abbrescia, D.I.; Mirizzi, A.; Tanzi, M., et al. Effect of a low glycemic index mediterranean diet on non-alcoholic fatty liver disease. J. Nutr. Heal. Aging 2017, 21, 404–412. [CrossRef] [PubMed]
48. Pérez-Guisado, J.; Muñoz-Serrano, A. The Effect of the Spanish Ketogenic Mediterranean Diet on Nonalcoholic Fatty Liver Disease: A Pilot Study. J. Med. Food 2011, 14, 677–680. [CrossRef] [PubMed]
49. Della Corte, C.; Mosca, A.; Vania, A.; Alterio, A.; Iasevoli, S.; Nobili, V. Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: The results of an Italian Study. Nutrition 2017, 39–40, 8–14. [CrossRef] [PubMed]
50. Papamiltiadous, E.S.; Roberts, S.K.; Nicoll, A.J.; Ryan, M.C.; Itsiopoulos, C.; Salim, A.; Tierney, A.C. A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): Study protocol. BMC Gastroenterol. 2016, 16, 14. [CrossRef] [PubMed]
51. Abenavoli, L.; Greco, M.; Nazionale, I.; Peta, V.; Milic, N.; Accattato, F.; Foti, D.; Gulletta, E.; Luzza, F. Effects of Mediterranean diet supplemented with silybin-vitaminE-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 2015, 1–9, 519–527. [CrossRef]
52. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016, 64, 1388–1402. [CrossRef]
53. Bach-Faig, A.; Berry, E.M.; Lairon, D.; Reguant, J.; Trichopoulou, A.; Dernini, S.; Medina, F.X.; Battino, M.; Belahsen, R.; Miranda, G., et al. Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr. 2011, 14, 2274–2284. [CrossRef] [PubMed]
54. Guo, X.; Yang, B.; Tang, J.; Li, D. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials. Clin. Nutr. 2017. [CrossRef] [PubMed]
55. Bozzetto, L.; Prinster, A.; Annuzzi, G.; Costagliola, L.; Mangione, A.; Vitelli, A.; Mazzarella, R.; Longobardo, M.; Mancini, M.; Vigorito, C., et al. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care 2012, 35, 1429–1435. [CrossRef] [PubMed]
56. Errazuriz, I.; Dube, S.; Slama, M.; Visentin, R.; Nayar, S.; O’Connor, H.; Cobelli, C.; Das, S.K.; Basu, A.; Kremers, W.K., et al. Randomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in Prediabetes. J. Clin. Endocrinol. Metab. 2017, 102, 1765–1774. [CrossRef] [PubMed]
57. Cantero, I.; Abete, I.; Monreal, J.; Martinez, J.; Zulet, M. Fruit Fiber Consumption Specifically Improves Liver Health Status in Obese Subjects under Energy Restriction. Nutrients 2017, 9, 667. [CrossRef] [PubMed]
58. Scribner, K.B.; Pawlak, D.B.; Ludwig, D.S. Hepatic Steatosis and Increased Adiposity in Mice Consuming Rapidly vs. Slowly Absorbed Carbohydrate. Obesity 2007, 15, 2190–2199. [CrossRef] [PubMed]
59. Valtueña, S.; Pellegrini, N.; Ardigò, D.; Del Rio, D.; Numeroso, F.; Scazzina, F.; Monti, L.; Zavaroni, I.; Brighenti, F. Dietary glycemic index and liver steatosis. Am. J. Clin. Nutr. 2006, 84, 136–142. [PubMed]
60. Dongiovanni, P.; Lanti, C.; Riso, P.; Valenti, L. Nutritional therapy for nonalcoholic fatty liver disease. J. Nutr. Biochem. 2016, 29, 1–11. [CrossRef] [PubMed]
61. Chen, G.; Ni, Y.; Nagata, N.; Xu, L.; Ota, T. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2016, 17, 1379. [CrossRef] [PubMed]
62. Sawangjit, R.; Chongmelaxme, B.; Phisalprapa, P.; Saokaew, S.; Thakkinstian, A.; Kowdley, K.V.; Chaiyakunapruk, N. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. Medicine 2016, 95, e4529. [CrossRef] [PubMed]
63. Li, J.; Cordero, P.; Nguyen, V.; Oben, J.A. The Role of Vitamins in the Pathogenesis of Non-alcoholic Fatty Liver Disease. Integr. Med. Insights 2016, 11, 19–25. [CrossRef] [PubMed]
64. Hernandez-Rodas, M.C.; Valenzuela, R.; Videla, L.A. Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2015, 16, 25168–25198. [CrossRef] [PubMed]
65. Yao, H.; Qiao, Y.-J.; Zhao, Y.-L.; Tao, X.-F.; Xu, L.-N.; Yin, L.-H.; Qi, Y.; Peng, J.-Y. Herbal medicines and nonalcoholic fatty liver disease. World J. Gastroenterol. 2016, 22, 6890–6905. [CrossRef] [PubMed]
66. Sugiura, M.; Nakamura, M.; Ogawa, K.; Ikoma, Y.; Yano, M. High serum carotenoids are associated with lower risk for developing elevated serum alanine aminotransferase among Japanese subjects: The Mikkabi cohort study. Br. J. Nutr. 2016, 115, 1462–1469. [CrossRef] [PubMed]
67. Ordonez, R.; Carbajo-Pescador, S.; Mauriz, J.L.; Gonzalez-Gallego, J. Understanding nutritional interventions and physical exercise in non-alcoholic fatty liver disease. Curr. Mol. Med. 2015, 15, 3–26. [CrossRef] [PubMed]
68. Houghton, D.; Stewart, C.J.; Day, C.P.; Trenell, M. Gut Microbiota and Lifestyle Interventions in NAFLD. Int. J. Mol. Sci. 2016, 17, 447. [CrossRef] [PubMed]
69. Lytle, K.A.; Wong, C.P.; Jump, D.B. Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice. PLoS ONE 2017, 12, e0173376. [CrossRef] [PubMed]
70. De Castro, G.S.; Calder, P.C. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clin. Nutr. 2017. [CrossRef] [PubMed]
71. Bozzetto, L.; Costabile, G.; Luongo, D.; Naviglio, D.; Cicala, V.; Piantadosi, C.; Patti, L.; Cipriano, P.; Annuzzi, G.; Rivellese, A.A. Reduction in liver fat by dietary MUFA in type 2 diabetes is helped by enhanced hepatic fat oxidation. Diabetologia 2016, 59, 2697–2701. [CrossRef] [PubMed]
72. Krishnan, S.; Cooper, J.A. Effect of dietary fatty acid composition on substrate utilization and body weight maintenance in humans. Eur. J. Nutr. 2014, 53, 691–710. [CrossRef] [PubMed]
73. Rivellese, A.A.; Giacco, R.; Annuzzi, G.; De Natale, C.; Patti, L.; Di Marino, L.; Minerva, V.; Costabile, G.; Santangelo, C.; Masella, R., et al. Effects of monounsaturated vs. saturated fat on postprandial lipemia and adipose tissue lipases in type 2 diabetes. Clin. Nutr. 2008, 27, 133–141. [CrossRef] [PubMed]
74. Summers, L.K.; Barnes, S.C.; Fielding, B.A.; Beysen, C.; Ilic, V.; Humphreys, S.M.; Frayn, K.N. Uptake of individual fatty acids into adipose tissue in relation to their presence in the diet. Am. J. Clin. Nutr. 2000, 71, 1470–1477. [PubMed]
75. Pachikian, B.D.; Essaghir, A.; Demoulin, J.-B.; Catry, E.; Neyrinck, A.M.; Dewulf, E.M.; Sohet, F.M.; Portois, L.; Clerbaux, L.-A.; Carpentier, Y.A., et al. Prebiotic approach alleviates hepatic steatosis: Implication of fatty acid oxidative and cholesterol synthesis pathways. Mol. Nutr. Food Res. 2013, 57, 347–359. [CrossRef] [PubMed]
76. Parnell, J.A.; Raman, M.; Rioux, K.P.; Reimer, R.A. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012, 32, 701–711. [CrossRef] [PubMed]
77. Brand-Miller, J.C.; Holt, S.H.A.; Pawlak, D.B.; McMillan, J. Glycemic index and obesity. Am. J. Clin. Nutr. 2002, 76, 281S–285S. [PubMed]
78. Jenkins, D.J.A.; Josse, A.R.; Labelle, R.; Marchie, A.; Augustin, L.S.A.; Kendall, C.W.C. Nonalcoholic fatty liver, nonalcoholic steatohepatitis, ectopic fat, and the glycemic index. Am. J. Clin. Nutr. 2006, 84, 3–4. [PubMed]
79. Rodriguez-Ramiro, I.; Vauzour, D.; Minihane, A.M. Polyphenols and non-alcoholic fatty liver disease: Impact and mechanisms. Proc. Nutr. Soc. 2016, 75, 47–60. [CrossRef] [PubMed]
80. Ni, Y.; Zhuge, F.; Nagashimada, M.; Ota, T. Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis. Nutrients 2016, 8, 391. [CrossRef] [PubMed]
81. Xin, J.; Zeng, D.; Wang, H.; Ni, X.; Yi, D.; Pan, K.; Jing, B. Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice. Appl. Microbiol. Biotechnol. 2014, 98, 6817–6829. [CrossRef] [PubMed]
82. Ritze, Y.; Bárdos, G.; Claus, A.; Ehrmann, V.; Bergheim, I.; Schwiertz, A.; Bischoff, S.C. Lactobacillus rhamnosus GG Protects against Non-Alcoholic Fatty Liver Disease in Mice. PLoS ONE 2014, 9, e80169. [CrossRef] [PubMed]
83. Peluso, I.; Romanelli, L.; Palmery, M. Interactions between prebiotics, probiotics, polyunsaturated fatty acids and polyphenols: Diet or supplementation for metabolic syndrome prevention? Int. J. Food Sci. Nutr. 2014, 65, 259–267. [CrossRef] [PubMed]
84. Takaki, A.; Kawai, D.; Yamamoto, K. Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH). Int. J. Mol. Sci. 2013, 14, 20704–20728. [CrossRef] [PubMed]
85. Loguercio, C.; Andreone, P.; Brisc, C.; Cristina, M.; Bugianesi, E.; Chiaramonte, M.; Cursaro, C.; Danila, M.; De Sio, I.; Floreani, A., et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic. Biol. Med. 2012, 52, 1658–1665. [CrossRef] [PubMed]
86. Cacciapuoti, F.; Scognamiglio, A.; Palumbo, R.; Forte, R.; Cacciapuoti, F. Silymarin in non alcoholic fatty liver disease. World J. Hepatol. 2013, 5, 109–113. [CrossRef] [PubMed]
87. Aller, R.; Izaola, O.; Tafur, C.; Berroa, E.; Mora, N.; Luis, D.A.D.E. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 3118–3124. [PubMed]
88. Sorrentino, G.; Crispino, P.; Coppola, D.; De Stefano, G. Efficacy of Lifestyle Changes in Subjects with Non-Alcoholic Liver Steatosis and Metabolic Syndrome May Be Improved with an Antioxidant Nutraceutical: A Controlled Clinical Study. Drugs R D 2015, 15, 21–25. [CrossRef] [PubMed]
89. Kawanaka, M.; Nishino, K.; Nakamura, J.; Suehiro, M.; Goto, D.; Urata, N.; Oka, T.; Kawamoto, H.; Nakamura, H.; Yodoi, J., et al. Treatment of nonalcoholic steatohepatitis with vitamins E and C: A pilot study. Hepatic Med. Evid. Res. 2013, 5, 11–16. [CrossRef] [PubMed]
90. Ersöz, G.; Günsar, F.; Karasu, Z.; Akay, S.; Batur, Y.; Akarca, U.S. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk. J. Gastroenterol. 2005, 16, 124–128. [PubMed]
91. Ebrahimi-Mameghani, M.; Jamali, H.; Mahdavi, R.; Kakaei, F.; Abedi, R.; Kabir-Mamdooh, B. Conjugated linoleic acid improves glycemic response, lipid profile, and oxidative stress in obese patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial. Croat. Med. J. 2016, 57, 331–342. [CrossRef] [PubMed]
92. Della Corte, C.; Carpino, G.; De Vito, R.; De Stefanis, C.; Alisi, A.; Cianfarani, S.; Overi, D.; Mosca, A.; Stronati, L.; Cucchiara, S., et al. Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. PLoS ONE 2016, 11, e0168216. [CrossRef] [PubMed]
93. Abidov, M.; Ramazanov, Z.; Seifulla, R.; Grachev, S. The effects of XanthigenTM in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes. Metab. 2010, 12, 72–81. [CrossRef] [PubMed]
94. Del Ben, M.; Polimeni, L.; Baratta, F.; Pastori, D.; Angelico, F. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br. J. Clin. Pharmacol. 2017, 83, 88–95. [CrossRef] [PubMed]
95. Trappoliere, M.; Caligiuri, A.; Schmid, M.; Bertolani, C.; Failli, P.; Vizzutti, F.; Novo, E.; di Manzano, C.; Marra, F.; Loguercio, C., et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J. Hepatol. 2017, 50, 1102–1111. [CrossRef] [PubMed]
96. Harrison, S.; Torgerson, S.; Hayashi, P.; Ward, J.; Schenker, S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2003, 98, 2485–2490. [CrossRef] [PubMed]
97. Alba, L.M.; Lindor, K. Non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2003, 17, 977–986. [CrossRef] [PubMed]
98. Foster, T.; Budoff, M.; Saab, S.; Ahmadi, N.; Gordon, C.; Guerci, A. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St Francis Heart Study randomized clinical trial. Am. J. Gastroenterol. 2011, 106, 71–77. [CrossRef] [PubMed]
99. Nobili, V.; Alisi, A.; Musso, G.; Scorletti, E.; Philip, C.; Byrne, C.D.; Nobili, V.; Alisi, A.; Musso, G.; Scorletti, E., et al. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Crit. Rev. Clin. Lab. Sci. 2016, 8363, 106–120. [CrossRef] [PubMed]
100. Hourigan, S.K.; Abrams, S.; Yates, K.; Pfeifer, K.; Torbenson, M.; Murray, K.; Roth, C.L.; Kowdley, K. The Relationship between Vitamin D Status and Non-alcoholic Fatty Liver Disease in Children. J. Pediatr. Gastroenterol. Nutr. 2016, 60, 396–404. [CrossRef] [PubMed]
101. Barchetta, I.; Carotti, S.; Labbadia, G.; Gentilucci, U.V.; Muda, A.O.; Angelico, F.; Silecchia, G.; Leonetti, F.; Fraioli, A.; Picardi, A., et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: Relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012, 56, 2180–2187. [CrossRef] [PubMed]
102. Lorvand Amiri, H.; Agah, S.; Tolouei Azar, J.; Hosseini, S.; Shidfar, F.; Mousavi, S.N. Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial. Clin. Nutr. 2016. [CrossRef] [PubMed]
103. Nobili, V.; Bedogni, G.; Alisi, A.; Pietrobattista, A.; Risé, P.; Galli, C.; Agostoni, C. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: Double-blind randomised controlled clinical trial. Arch. Dis. Child. 2011, 96, 350–353. [CrossRef] [PubMed]
104. Gupta, V.; Mah, X.; Garcia, M.C.; Antonypillai, C.; Van Der Poorten, D.; Gupta, V.; Mah, X.; Garcia, M.C.; Antonypillai, C.; Van Der Poorten, D. Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease. World J. Gastroenterol. 2015, 21, 10621–10635. [CrossRef] [PubMed]
105. Mokhtari, Z.; Gibson, D. L.; Hekmatdoost, A. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Adv. Nutr. Int. Rev. J. 2017, 15, 240–252. [CrossRef] [PubMed]
106. Sáez-Lara, M.J.; Robles-Sanchez, C.; Ruiz-Ojeda, F.J.; Plaza-Diaz, J.; Gil, A. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. Int. J. Mol. Sci. 2016, 13, 928. [CrossRef] [PubMed]
107. Le Roy, T.; Llopis, M.; Lepage, P.; Bruneau, A.; Rabot, S.; Bevilacqua, C.; Martin, P.; Philippe, C.; Walker, F.; Bado, A., et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013, 62, 1784–1794.
108. Eslamparast, T.; Poustchi, H.; Zamani, F.; Sharafkhah, M.; Malekzadeh, R.; Hekmatdoost, A. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Am. J. Clin. Nutr. 2014, 99, 535–542. [CrossRef] [PubMed]
109. Mofidi, F.; Poustchi, H.; Yari, Z.; Nourinayyer, B.; Merat, S.; Sharafkhah, M.; Malekzadeh, R.; Hekmatdoost, A. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: A pilot, randomised, double-blind, placebo-controlled, clinical trial. Br. J. Nutr. 2017, 117, 662–668. [CrossRef] [PubMed]
110. Asgharian, A.; Askari, G.; Esmailzade, A.; Feizi, A.; Mohammadi, V. The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. Int. J. Prev. Med. 2016, 7, 59. [CrossRef] [PubMed]
111. Ekhlasi, G.; Zarrati, M.; Agah, S.; Hosseini, A.F.; Hosseini, S. Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease. EXCLI J. 2017, 20, 278–290.
112. Ekhlasi, G.; Kolahdouz Mohammadi, R.; Agah, S.; Zarrati, M.; Hosseini, A.; Arabshahi, S.; Shidfar, F. Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J. Res. Med. Sci. 2016, 21, 106. [CrossRef] [PubMed]
113. Malaguarnera, M.; Vacante, M.; Antic, T.; Giordano, M.; Chisari, G.; Acquaviva, R.; Mastrojeni, S.; Malaguarnera, G.; Mistretta, A.; Volti, G.L., et al. Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis. Dig. Dis. Sci. 2012, 57, 545–553. [CrossRef] [PubMed]
114. Ferolla, S.M.; Couto, C.A.; Costa-silva, L.; Armiliato, G.N.A.; Pereira, C.A.S.; Martins, F.S.; Ferrari, M.D.L.A.; Vilela, E.G.; Torres, H.O.G.; Cunha, A.S., et al. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016, 8, 397. [CrossRef] [PubMed]
115. Feig, D.; Kang, D.; Johnson, R. Uric acid and cardiovascular risk. N. Engl. J. Med. 2009, 359, 1811–1821. [CrossRef] [PubMed]
116. Byrne, C.D.; Targher, G. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016, 59, 1141–1144. [CrossRef] [PubMed]
117. Rinella, M.E. Nonalcoholic Fatty Liver Disease. JAMA 2015, 313, 2263. [CrossRef] [PubMed]
118. Martel, C.; Esposti, D.D.; Bouchet, A.; Brenner, C.; Lemoine, A. Non-alcoholic steatohepatitis: New insights from OMICS studies. Curr. Pharm. Biotechnol. 2012, 13, 726–735. [CrossRef] [PubMed]
119. Zhang, X.; Wang, Y.; Liu, P. Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease. Protein Cell 2017, 8, 4–13. [CrossRef] [PubMed]
120. Dongiovanni, P.; Romeo, S.; Valenti, L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed. Res. Int. 2015, 2015, 460190. [CrossRef] [PubMed]
121. Ravi Kanth, V.V.; Sasikala, M.; Sharma, M.; Rao, P.N.; Reddy, D.N. Genetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to management. World J. Hepatol. 2016, 8, 827–837. [CrossRef] [PubMed]
122. Lim, J.W.; Dillon, J.; Miller, M. Proteomic and genomic studies of non-alcoholic fatty liver disease-clues in the pathogenesis. World J. Gastroenterol. 2014, 20, 8325–8340. [CrossRef] [PubMed]
123. Anstee, Q.M.; Day, C.P. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 645–655. [CrossRef] [PubMed]
124. Wruck, W.; Graffmann, N.; Kawala, M.-A.; Adjaye, J. Concise Review: Current Status and Future Directions on Research Related to Nonalcoholic Fatty Liver Disease. Stem Cells 2017, 35, 89–96. [CrossRef] [PubMed]
125. Moylan, C.A.; Pang, H.; Dellinger, A.; Suzuki, A.; Garrett, M.E.; Guy, C.D.; Murphy, S.K.; Ashley-Koch, A.E.; Choi, S.S.; Michelotti, G.A., et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 2014, 59, 471–482. [CrossRef] [PubMed]
126. Ladaru, A.; Balanescu, P.; Stan, M.; Codreanu, I.; Anca, I.A. Candidate proteomic biomarkers for non-alcoholic fatty liver disease (steatosis and non-alcoholic steatohepatitis) discovered with mass-spectrometry: A systematic review. Biomarkers 2016, 21, 102–114. [CrossRef] [PubMed]
127. Nicholson, J.K.; Lindon, J.C. Systems biology: Metabonomics. Nature 2008, 455, 1054–1056. [CrossRef] [PubMed]
128. Yu, M.; Zhu, Y.; Cong, Q.; Wu, C. Metabonomics Research Progress on Liver Diseases. Can. J. Gastroenterol. Hepatol. 2017, 2017, 1–10. [CrossRef] [PubMed]
129. De Mello, V.D.; Matte, A.; Perfilyev, A.; Männistö, V.; Rönn, T.; Nilsson, E.; Käkelä, P.; Ling, C.; Pihlajamäki, J. Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action. Epigenetics 2017, 12, 287–295. [CrossRef] [PubMed]
130. Lee, J.; Kim, Y.; Friso, S.; Choi, S.-W. Epigenetics in non-alcoholic fatty liver disease. Mol. Asp. Med. 2017, 54, 78–88. [CrossRef] [PubMed]
131. Gallego-Durán, R.; Romero-Gómez, M. Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. World J. Hepatol. 2015, 7, 2497–2502. [CrossRef] [PubMed]
132. Bashiardes, S.; Shapiro, H.; Rozin, S.; Shibolet, O.; Elinav, E. Non-alcoholic fatty liver and the gut microbiota. Mol. Metab. 2016, 5, 782–794. [CrossRef] [PubMed]
133. Hasin, Y.; Seldin, M.; Lusis, A.; Guo, W.; Go, J.; Shi, H.; Downey, P.; Elliott, P.; Green, J.; Landray, M. Multi-omics approaches to disease. Genome Biol. 2017, 18, 83. [CrossRef] [PubMed]
134. Ritchie, M.D.; Holzinger, E.R.; Li, R.; Pendergrass, S.A.; Kim, D. Methods of integrating data to uncover genotype–phenotype interactions. Nat. Rev. Genet. 2015, 16, 85–97. [CrossRef] [PubMed]
135. Wood, G.C.; Chu, X.; Argyropoulos, G.; Benotti, P.; Rolston, D.; Mirshahi, T.; Petrick, A.; Gabrielson, J.; Carey, D.J.; DiStefano, J.K., et al. A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci. Rep. 2017, 7, 43238. [CrossRef] [PubMed]
136. Mardinoglu, A.; Bjornson, E.; Zhang, C.; Klevstig, M.; Söderlund, S.; Ståhlman, M.; Adiels, M.; Hakkarainen, A.; Lundbom, N.; Kilicarslan, M., et al. Personal model-assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD. Mol. Syst. Biol. 2017, 13, 916. [CrossRef] [PubMed]
137. Lau, J.K.C.; Zhang, X.; Yu, J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J. Pathol. 2017, 241, 36–44. [CrossRef] [PubMed]
138. Cordero, P.; Campion, J.; Milagro, F.I.; Martinez, J.A. Transcriptomic and epigenetic changes in early liver steatosis associated to obesity: Effect of dietary methyl donor supplementation. Mol. Genet. Metab. 2013, 110, 388–395. [CrossRef] [PubMed]
139. Wang, C.; Liu, W.; Yao, L.; Zhang, X.; Zhang, X.; Ye, C.; Jiang, H.; He, J.; Zhu, Y.; Ai, D. Hydroxyeicosapentaenoic acids and epoxyeicosatetraenoic acids attenuate early occurrence of nonalcoholic fatty liver disease. Br. J. Pharmacol. 2017, 174, 2358–2372. [CrossRef] [PubMed]
140. Stiuso, P.; Scognamiglio, I.; Murolo, M.; Ferranti, P.; De Simone, C.; Rizzo, M.R.; Tuccillo, C.; Caraglia, M.; Loguercio, C.; Federico, A. Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: A pilot study. Oxid. Med. Cell. Longev. 2014, 2014, 1–8. [CrossRef] [PubMed]
141. Cheng, J.; Joyce, A.; Yates, K.; Aouizerat, B.; Sanyal, A.J. Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH). PLoS ONE 2012, 7, e44106. [CrossRef] [PubMed]